Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.

Takashi Kojima Manish A ShahKei MuroEric FrancoisAntoine AdenisChih-Hung HsuToshihiko Doi Toshikazu Moriwaki Sung-Bae Kim Se-Hoon LeeJaafar BennounaKen Kato Lin ShenPeter EnzingerShu-Kui QinPaula FerreiraJia ChenGustavo C Girotto Christelle De La FouchardièreHelene SenellartRaed Al-RajabiFlorian LordickRuixue WangShailaja SuryawanshiPooja BhagiaS Peter KangJean-Philippe Metgesnull null

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)

Pembrolizumab prolonged OS versus chemotherapy as second-line therapy for advanced esophageal cancer in patients with PD-L1 CPS ≥ 10, with fewer treatment-related adverse events.

Keyphrases

phase iii
open label
phase ii
double blind
clinical trial
placebo controlled
locally advanced
advanced non small cell lung cancer
squamous cell carcinoma
radiation therapy
randomized controlled trial